Mizuho Securities analyst Uy Ear reiterated a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) today and set a price target of $58.00. The company’s shares closed last Friday at $17.41, close to its 52-week low of $14.16.
According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.2% and a 28.6% success rate. Ear covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Avrobio, and uniQure.
Arcutis Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $46.50.
The company has a one-year high of $38.49 and a one-year low of $14.16. Currently, Arcutis Biotherapeutics has an average volume of 176.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Read More on ARQT:
- Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Cytokinetics (CYTK)
- Air Products & Chemicals, Inc. Updates 1 Key Risk Factor
- Starbucks Partners with Meituan to Enhance Coffee Delivery in China
- Ralph Lauren CEO Talks about Metaverse
- Micron Stock: Will the Uptrend Sustain?